The 2004 WHO classification of bladder tumors: a summary and commentary.
about
CCL18 in a multiplex urine-based assay for the detection of bladder cancerMolecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data.A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.Long-term oncologic outcomes after radical cystectomy for bladder cancer at a single institution.Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinomaRisk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.IL-8 as a urinary biomarker for the detection of bladder cancer.Interobserver agreement of confocal laser endomicroscopy for bladder cancerA multi-analyte assay for the non-invasive detection of bladder cancer.Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells.Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.Comparison of dynamic contrast-enhanced and diffusion weighted magnetic resonance image in staging and grading of carcinoma bladder with histopathological correlation.Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea.Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.High prevalence of TERT promoter mutations in micropapillary urothelial carcinomaEffects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and CancerNatural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohortCCR7 as a predictive biomarker associated with computed tomography for the diagnosis of lymph node metastasis in bladder carcinomaA critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change?Superficial bladder cancer: part 1. Update on etiology, classification and natural history.Role of maspin in cancer.Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing.Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional studyBladder cancer: clinical and pathological profile.Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder.Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.Diagnosis and management of urothelial carcinoma of the bladder.Diagnosis and treatment of bladder cancer: how can we improve?Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancerDHCR24 is an independent predictor of progression in patients with non-muscle-invasive urothelial carcinoma, and its functional role is involved in the aggressive properties of urothelial carcinoma cells.Differentially expressed genes and microRNAs in bladder carcinoma cell line 5637 and T24 detected by RNA sequencing.Repeated endoscopic treatments of multiple recurrent ureteral tumors following 15-year-long history of bladder tumors in the patient from endemic nephropathy regionNext-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer.HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).Preventive effect of intravesical ozone supplementation on n-methyl-n-nitrosourea-induced non-muscle invasive bladder cancer in male rats
P2860
Q28729838-BB34FE3F-CBD5-40DA-BC15-84BEF3591F59Q30433431-9BF928AA-FA0A-4763-8B5E-619D6332BC25Q31103185-40AE0420-EE0A-4C4A-8CB2-6ABA0A32884FQ31112817-A0CBD392-5BF3-438A-B2DE-3DBF442798B5Q33581255-4042D1E5-C030-42E7-A535-AD5A083EAFAFQ33627559-C3D754C5-A246-42C8-984B-E1E8160198BEQ33686437-D1A69C80-10C9-4C87-ABBF-414874639783Q33721258-7945FC4C-D1CD-4778-BF8F-C2EA2BE47D82Q34258579-80D7713E-D541-437B-B5DA-DAC3EC7E3B9BQ34448486-636E6771-BE69-4602-BE01-2DB58055452AQ34456333-F76C5EA2-2991-4D4B-8C79-D9C360E301E7Q34533542-7BB52B53-E56E-4597-982F-4DD6A41A086DQ34570737-21362C4C-5C25-44D9-A8FB-126DCC00908AQ34866510-DD74A1D9-FA22-47A5-B9E7-4BBDE0BAB392Q35218358-E6BC40B8-ECA2-4A26-A2AC-B35BADD7A405Q35905142-097B910B-0D3C-4208-B452-F2F421CE37C2Q35926074-3F93842F-E501-464D-9B9A-1ED807A1C6F8Q35953342-0097CADE-38F1-4131-8229-2DABE49A0871Q36103321-2273D4AE-B049-4492-835D-8D4AAFD20787Q36127825-80FEF8EF-1695-409E-ABD2-23FC2CF60C84Q36487162-2FB6BF66-560D-4747-A7D2-CA7ECD590D52Q36502834-A54485A7-B67D-431C-AEB4-D6C9FBFD3857Q36677567-5FBB6E74-9762-4CB4-A834-3F09F3709F5CQ36689131-A2E2EFEE-D63D-4311-A71B-45B3247DF53AQ36698729-D821393A-486C-43A3-BFD6-958D7A4067BBQ36826036-330B0485-3AF7-4299-B2A7-339BEFACB4E3Q37165228-3BA56B33-7B2B-45DC-AC85-84459C016007Q37278983-B0D59AA5-C92D-4A35-84AB-AA3D65A0C887Q37407149-1D48B6D3-BE4C-4610-9070-93F1FDAE545EQ37705271-B7BE1716-7918-4932-AF9B-1C91763CFD4AQ37874887-F65B7E0F-030D-4A9F-BB5B-5A6548174675Q38018207-94DD02F8-089D-48DC-ABC5-704D5BC5D0DEQ38269990-4E9B8DD1-6176-4BA0-B8A2-3A570711F221Q38441122-434EB244-5F9B-4864-AF91-B05F896D0DFEQ38452817-F4F05D0E-7F86-47F2-BFCE-F21DDDFC1CEDQ38603697-37304F58-943A-4D9A-9EBC-E2D0365319F0Q40275671-DBB76730-8A70-42B5-B4F0-CF044D68FEE4Q40427246-5D64060F-5A47-45D4-8924-B184DE176F33Q40713928-9736FA95-AC62-4A49-97E4-3A366D2EDFFBQ41244889-19E7998D-2163-4898-BBC5-FCBDCA4DE479
P2860
The 2004 WHO classification of bladder tumors: a summary and commentary.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The 2004 WHO classification of bladder tumors: a summary and commentary.
@ast
The 2004 WHO classification of bladder tumors: a summary and commentary.
@en
type
label
The 2004 WHO classification of bladder tumors: a summary and commentary.
@ast
The 2004 WHO classification of bladder tumors: a summary and commentary.
@en
prefLabel
The 2004 WHO classification of bladder tumors: a summary and commentary.
@ast
The 2004 WHO classification of bladder tumors: a summary and commentary.
@en
P2860
P1476
The 2004 WHO classification of bladder tumors: a summary and commentary.
@en
P2093
Antonio Lopez-Beltran
P2860
P304
P356
10.1177/106689690501300203
P577
2005-04-01T00:00:00Z